Alnylam Canada Signs LOI From Pan-Canadian Pharmaceutical Alliance For The Public Reimbursement Of AMVUTTRA For The Treatment Of Hereditary Transthyretin-Mediated Amyloidosis In Adults
Express News | Alnylam Canada Signs Letter of Intent From Pan-Canadian Pharmaceutical Alliance for the Public Reimbursement of Amvuttra® for the Treatment of Hereditary Transthyretin-Mediated (Hattr) Amyloidosis in Adults
H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $400
Press Release: Alnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial Results
Alnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial Results
JAZZ Stock Soars After Combo Therapy Meets Goal in Lung Cancer Study
IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug
Scotiabank Initiates Alnylam Pharmaceuticals at Sector Outperform With $305 Price Target
Express News | Alnylam Pharmaceuticals Inc - Helios-B Phase 3 Study Met All Primary and Secondary Endpoints
Express News | Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of Attr Amyloidosis With Cardiomyopathy
Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis With Cardiomyopathy
BofA Securities Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Raises Target Price to $314
Alnylam Pharmaceuticals Is Maintained at Buy by Chardan Capital
Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $220 Price Target
$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Hold Rating on Alnylam Pharmaceuticals Amid Vutrisiran Commercialization Challenges
A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $275 to $342
Alnylam Pharmaceuticals Price Target Maintained With a $320.00/Share by Needham
Alnylam Pharmaceuticals Analyst Ratings
Balancing Promise and Caution: A Hold Rating for Alnylam Pharmaceuticals Amid Evolving Market Dynamics